Telecoms.com Intelligence's Annual Industry Survey Highlights Increasing Importance Of 'Designed-For' B2B BSS Solutions
16.12.2019 12:00:00 EET | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider, in collaboration with Telecoms.com Intelligence, today announced the findings of their 2019 Annual Industry Survey Report. In the report, dedicated and designed-for modern B2B BSS solutions were highlighted as a key requirement by Communication Service Providers (CSPs), with 84% of respondents identifying B2B as the area where enterprise customers will generate the highest revenue growth in 2020 and beyond.
Based on 540 responses to a survey, the report took an overview of the industry landscape over the last 12 months and provided projections for activity from 2020 and beyond. The OSS/BSS section of the survey highlighted that the B2B segments, including large enterprises (30%), small- and medium-sized enterprises (SMEs) (19%), small office/home office (SOHO) (17%), as well as public sector and wholesale partners, need to be served by a specialist B2B BSS platform. This platform should offer a dedicated digital engagement approach supporting personalised order, workflow and service management demands of enterprises, resellers and partners.
According to the survey, 50% of CSPs already have a separate platform to reflect this sector's demand, and 50% of these require a more digital approach to market engagement. 90% of CSPs agreed that the SME segment specifically requires real-time usage and control and the ability to configure, price and order services via online tools. Defined by service level agreements, business customers often demand higher levels of customisation, shorter time to market for new services, and tend to be less tolerant of failures. But at the same time, they are also less sensitive to price, compared with the consumer market.
Flexibility and customisation for both CSPs and enterprise is also especially important in 5G with its strong virtualisation and software-centric characteristics. The B2B sector is forecast to significantly outweigh the B2C sector as a major source of revenue from 5G services and the report reinforced how important 5G technology is in shaping and scheduling future projects. A staggering 97% of CSPs will use SDN/NFV environments to allow integrated services to be personalised, demonstrating that virtualisation will trigger major BSS change.
Gary Bunney, CEO, MDS Global said, "Currently, most BSS running in Communication Service Providers are hardwired to support traditional enterprise services and incorporate many offline business processes that require high-cost specialist resources to deliver constant change."
He continues, "Today’s market demands low-cost service agility. MDS Global is uniquely placed to assist CSPs in automating service engagement whilst enabling the opportunity that 5G and service personalisation brings to enterprises. We provide a dedicated B2B BSS-as-a-Service platform, decreasing the costs associated with operations, automating customer engagement and providing agility to ensure our CSP customers are able to invent, tailor and launch new services without the hindrance of engineering challenges."
MDS Global's B2B-on-Demand enables cost-efficiency and dedicated service delivery. Download the Telecoms.com Insight 2019 Annual Industry Survey here.
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions, look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191216005010/en/
Contact information
Martine Naughton
MDS Global
Email: martine.naughton@mdsglobal.com
Tel: +44 (0) 7909 475815
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom